• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Evidence Links 5 & 1 Plan® to Improved Metabolic Health Outcomes

    9/15/25 8:30:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples
    Get the next $MED alert in real time by email

    New data findings show the Optimal Weight 5 & 1 plan® delivers metabolic health benefits beyond weight loss, helping preserve 98% of lean mass1

    9 out of 10 Americans are metabolically unhealthy, which is an underlying driver of some of the most serious age-related health challenges of our time 2

    With more than 90% of U.S. adults classified as metabolically unhealthy1, the silent crisis of metabolic dysfunction continues to escalate. This condition can be linked to a range of challenges, including being overweight and having difficulty maintaining energy, vitality and long-term health and wellbeing. To address this issue, Medifast, the 40+ year old health and wellness company known for its science-backed, coach-guided lifestyle system, is reinforcing its commitment to advancing metabolic health through its innovative, clinically supported plans.

    New Findings: Preserving Lean Mass, Driving Healthier Outcomes

    Analysis of biobank data and a review of thousands of data points from the company's clinical trial revealed a breakthrough finding: individuals on the company's 5 & 1 plan preserved 98% of lean mass after 16 weeks on the program2. Lean mass is critical for optimal metabolic health because it drives basal metabolic rate (BMR), which supports efficient energy use and helps regulate body weight.

    "Metabolic dysfunction is more than just a health issue — it's an invisible epidemic that impacts energy, mood, hormones, and long-term wellness. When metabolic health is off, everything feels off," said Dr. Holly Lofton, Director of the Medical Weight Management Program at NYU Grossman School of Medicine, where she serves as a practicing physician, and a member of Medifast's Scientific Advisory Board. "Today, many people are living with the daily consequences of metabolic dysfunction, often without even knowing it. It's not just about the numbers on the scale; it can be about fatigue that keeps you from playing with your kids, weight that feels impossible to manage, or chronic conditions that chip away at your quality of life."

    Scientific Leadership and the Fight Against Metabolic Dysfunction

    With more than four decades of experience, Medifast has built a strong foundation of scientific evidence, including more than 30 research studies, 70+ peer-reviewed scientific abstract presentations and publications, and more than 30 peer-reviewed scientific publications. The company continues to invest in advancing science through comprehensive literature reviews, exploratory research, and planned future clinical trials — all designed to advance its understanding of optimal metabolic health.

    "As the metabolic health crisis has grown, we've gone deeper into both our own clinical trial data and the broader body of research," said Satya Jonnalagadda, PhD, MBA, RDN, Vice President of Scientific & Clinical Affairs at Medifast. "The evidence is clear: the 5 & 1 Plan doesn't just promote healthy, quality weight loss. It unlocks a body that works better over time and improves key drivers of metabolic health.3"

    Looking Ahead

    Jonnalagadda continued, "We're committed to expanding our scientific and clinical contributions and making an impact on optimal metabolic health. Our approach to helping to reverse the effects of metabolic dysfunction is grounded in science and fueled by support from a coach and community — with the goal of impacting lives at scale."

    Later this month, Medifast will host its Scientific Advisory Board meeting, where a group of distinguished physicians, academic researchers, nutrition, exercise science, and bio-behavioral science experts will explore the latest research on metabolic dysfunction and discuss new opportunities for the company to continue supporting optimal metabolic health. Looking ahead, Medifast will unveil the next phase of its scientific discovery, underscoring its commitment to helping people achieve optimal metabolic health.

    About Medifast: Medifast (NYSE:MED) is the health and wellness company offering a simple yet comprehensive approach to weight management and lifestyle change through its science-backed and coach-guided lifestyle system. Designed to address the challenges of metabolic dysfunction, the company's lifestyle system integrates personalized plans, scientifically developed products and a framework for habit creation — all supported by a unique network of independent coaches. Science is core to the company, marked by an in-house Scientific & Clinical Affairs team and independent esteemed Scientific Advisory Board, 30+ research studies, 70+ scientific abstract presentations and publications, and 30+ publications in peer-reviewed scientific journals. With more than 40 years of clinical heritage, Medifast is addressing the metabolic health crisis through cutting-edge science and community-driven support and remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature®. For more information, visit MedifastInc.com, and follow Medifast on X and LinkedIn.

    1 O'Hearn M, et al. Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. J Am Coll Cardiol. 2022;80(2):138-151. doi: 10.1016/j.jacc.2022.04.046.

    2 Arterburn LM, et al. Randomized controlled trial assessing two commercial weight loss programs in adults with overweight or obesity. Obes Sci Pract. 2018;5(1):3-14. doi: 10.1002/osp4.312. In a clinical study, individuals on the OPTAVIA 5&1 Plan retained 98% of lean mass at 16 weeks.

    3 Cesaro A, et al. Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options. Front Cardiovasc Med. 2023;10:1187735. doi: 10.3389/fcvm.2023.1187735

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250912366555/en/

    Public Relations:

    Jessica Oring, [email protected]

    Get the next $MED alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MED

    DatePrice TargetRatingAnalyst
    11/5/2024$16.50 → $17.00Underperform → Neutral
    DA Davidson
    6/5/2024$25.00 → $17.50Neutral → Underperform
    DA Davidson
    10/13/2023$82.00Equal-Weight
    Stephens
    11/4/2022$278.00 → $106.00Buy → Neutral
    DA Davidson
    8/4/2022$345.00 → $150.00Buy → Hold
    Jefferies
    2/24/2022$349.00 → $341.00Buy
    DA Davidson
    11/8/2021$395.00 → $349.00Buy
    DA Davidson
    More analyst ratings

    $MED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evidence Links 5 & 1 Plan® to Improved Metabolic Health Outcomes

    New data findings show the Optimal Weight 5 & 1 plan® delivers metabolic health benefits beyond weight loss, helping preserve 98% of lean mass1 9 out of 10 Americans are metabolically unhealthy, which is an underlying driver of some of the most serious age-related health challenges of our time 2 With more than 90% of U.S. adults classified as metabolically unhealthy1, the silent crisis of metabolic dysfunction continues to escalate. This condition can be linked to a range of challenges, including being overweight and having difficulty maintaining energy, vitality and long-term health and wellbeing. To address this issue, Medifast, the 40+ year old health and wellness company known for i

    9/15/25 8:30:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Announces Second Quarter 2025 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2025. Second Quarter 2025 Revenue: $105.6 million, with revenue per active earning coach of $4,630 Active Coaches: Independent active earning OPTAVIA coaches of 22,800 Net Income: $2.5 million or $0.22 per diluted share, which includes a gain on investment in LifeMD (NASDAQ:LFMD) common stock of $2.0 million (net of tax) Strong Balance Sheet: $162.7 million in cash, cash equivalents, and investment securities with no debt "We are working diligently to transform our business as we look to he

    8/4/25 4:05:00 PM ET
    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples

    Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2025

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the quarter ended June 30, 2025 on Monday, August 4, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on August 4, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at https:

    7/21/25 4:05:00 PM ET
    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples

    $MED
    SEC Filings

    View All

    SEC Form S-8 filed by MEDIFAST INC

    S-8 - MEDIFAST INC (0000910329) (Filer)

    8/4/25 4:56:26 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form 10-Q filed by MEDIFAST INC

    10-Q - MEDIFAST INC (0000910329) (Filer)

    8/4/25 4:51:19 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    MEDIFAST INC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    8/4/25 4:07:38 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medifast upgraded by DA Davidson with a new price target

    DA Davidson upgraded Medifast from Underperform to Neutral and set a new price target of $17.00 from $16.50 previously

    11/5/24 7:48:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast downgraded by DA Davidson with a new price target

    DA Davidson downgraded Medifast from Neutral to Underperform and set a new price target of $17.50 from $25.00 previously

    6/5/24 7:15:11 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Stephens initiated coverage on Medifast with a new price target

    Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00

    10/13/23 7:41:39 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Xian Ming

    4 - MEDIFAST INC (0000910329) (Issuer)

    6/26/25 7:06:44 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Director Schlackman Scott was granted 11,168 shares, increasing direct ownership by 78% to 25,549 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    6/26/25 7:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Director Thomas Andrea B was granted 11,168 shares, increasing direct ownership by 87% to 24,017 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    6/26/25 7:04:28 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Chard Daniel R bought $5,003 worth of shares (381 units at $13.13) (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    6/17/25 6:20:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Thomas Andrea B bought $3,471 worth of shares (50 units at $68.89), increasing direct ownership by 0.81% to 6,253 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    11/9/23 8:20:19 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Hoer Michael A. bought $3,428 worth of shares (50 units at $68.89), increasing direct ownership by 0.60% to 8,375 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    11/9/23 8:20:03 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Leadership Updates

    Live Leadership Updates

    View All

    KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

    6/7/24 6:09:00 PM ET
    $ADTN
    $ALTR
    $ATNI
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology

    Medifast Appoints Steven Zenker as Vice President of Investor Relations

    BALTIMORE, March 2, 2023 /PRNewswire/ -- Medifast (NYSE:MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today announced it has named Steven Zenker as Vice President of Investor Relations. Mr. Zenker has over 30 years of investor relations, financial planning and analysis, communications, and investment management experience. He reports to Chief Financial Officer Jim Maloney and will lead the strategy and continued implementation of the company's investor relations program. "We are pleased to welcome Steven to the Medifast t

    3/2/23 8:30:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Financials

    Live finance-specific insights

    View All

    Medifast Announces Second Quarter 2025 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the second quarter ended June 30, 2025. Second Quarter 2025 Revenue: $105.6 million, with revenue per active earning coach of $4,630 Active Coaches: Independent active earning OPTAVIA coaches of 22,800 Net Income: $2.5 million or $0.22 per diluted share, which includes a gain on investment in LifeMD (NASDAQ:LFMD) common stock of $2.0 million (net of tax) Strong Balance Sheet: $162.7 million in cash, cash equivalents, and investment securities with no debt "We are working diligently to transform our business as we look to he

    8/4/25 4:05:00 PM ET
    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples

    Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2025

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the quarter ended June 30, 2025 on Monday, August 4, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on August 4, 2025. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or directly at https:

    7/21/25 4:05:00 PM ET
    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples

    Medifast Announces First Quarter 2025 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (NASDAQ:LFMD) common stock of $0.4 million (net of tax) Loss per share of $0.07 Cash, Cash Equivalents, and Investment Securities of $164.6 million with no debt "In today's health and wellness landscape, more people than ever are seeking guidance not just for we

    4/28/25 4:05:00 PM ET
    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples

    $MED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MEDIFAST INC

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    7/10/24 1:14:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G filed by MEDIFAST INC

    SC 13G - MEDIFAST INC (0000910329) (Subject)

    7/1/24 4:18:04 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G/A filed by MEDIFAST INC (Amendment)

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    2/13/24 10:36:09 AM ET
    $MED
    Packaged Foods
    Consumer Staples